مشروعات صندوق البحوث بكلية الصيدلة
 


  • النشاط المضاد للأورام لبعض المواد المعدلة للجهاز المناعى .
    كود المشروع
    Code:TU-10-34-2009
    الباحث الرئيسي
    أ.د / علاء الدين السيد السيسى الاستاذ بالكلية
    لجنة المتابعه
    أ.د / فاطمة ابراهيم سنبل وكيل كلية الصيدلة للدراسات العليا والبحوث أ.د / طارق السعيد البنا أستاذ ورئيس قسم الميكروبيولوجيا بكلية الصيدلة
    مدة المشروع
    عام اعتبارا من 9 /8 /2009 حتي 8 /8 /2010

  • تقييم التلوث البيولوجي للماء من مصادر مختلفة في محافظة الغربية
    ميزانية المشروع 100000 جنيه
    تاريخ البدء 1/7/2000
    تاريخ الإنتهاء 24/12/2005
    الباحث الرئيسي الأستاذ الدكتور / وجية محمود عوارة
    الهدف من المشروع

    Summary
    Pollution from industrial, agricultural and domestic sources is constantly reducing water quality worldwide. This, in turn, is leading to the serious degradation of ecosystems and constituting a direct threat to public health.

    Most of pollution screening studies is mainly depending on measuring chemical pollutants either organic or inorganic. In Egypt, few data are available on the degree as well as the profile of biological water pollution.

    It is apparent that biological pollution has a significant correlation with most of infectious diseases. Water and food are believed to be important sources of infections in Egypt. However, water represent the Most important source of pollution in Egypt due to many unhygienic and unhealthy practices on dealing with water either rive Nile or open canals.

    Raw sewage, or sewage that has not been treated adequately, is one serious source of water pollution. The solid waste (sludge) may be spread over fields as a fertilizer or dumped at rivers or sea leading to unacceptably high bacterial content.

    A major scientific and technological effort is needed to detect and manage water resources.

    Objectives:

    1. The main objective of this project is to detect and/or measure the biological pollution of water from different sources in Gharbia region.
    2. Isolation of the different types of microbial contamination such as bacteria, protozoa and parasites from water.
    3. Identification of these microbes by specific methods.
    4. Attempt to select or develop a bacterial strain that has the ability of detoxification of the toxic organic mercurial compounds to non toxic volatile mercury.

     


  • حامض الهيموسيستين الاميني في بلازما الدم
    ميزانية المشروع
    100000 جنيه
    تاريخ البدء
    31/7/2000
    تاريخ الإنتهاء
    عامان 
    الباحث الرئيسي
    الأستاذ الدكتور / مختار محمد مبروك
    الهدف من المشروع

    Summary and Explanation of the Clinical Problem:
    Homocysteine is the next cholesterol, because homocysteine may be just as important as cholesterol in predicating the risk clogged probably be discussing our "homocysteine level" with health care providers, and family. Why? Because homocysteine is an important new risk factor for heat disease and myocardial infraction.

    Most deaths in industrialized and developing countries are caused by cardiovascular diseaqse and arteriosclerosis. Numerous possible risk factors for these diseases have been identified, including high blood cholesterol levels, hypertension, diabetes and smoking. These risk factor can only account for about 50% of the cases, therefore it is clear, That other risk factors must exist. Several recent studies have shown that Hemocysteine is a potent an arteriosclerotic agent.

    Homocysteine is a sulfur containing amino acid and it is a branch-point metabolite, the biological fate of which is linked to vitamin B12, reduced folates and vitamin B6 . Various defects in homocysteine metabolism, among which cystathionine beta-synthestse deficiency, lead to homocystinuria and premature arteriosclerosis. Impaired Hemocysteine metabolism seems to exist in 15-30 per cent of patients with premature cardiovascular disease, arteriosclerosis and thrombosis. Beside dietary low vitamin B6/B12 or folate levels, inborn errors of Vitamin B12 and/or Folate transport cause an accumulation of homocysteine.

    Normally the plasma level of homocysteine is about 5-15 umol/L, Some researchers concluded that a 5 umol/L increment in homocysteine level raises coronary artery disease risk as much as a 20 mg/dl rise in Cholesterol.

    Unfortunately, however, Hemocysteine level are net usually tested on an individual basis. The test available to measure Hemocysteine are expensive and have not yet made their way into General Medical Screening Protocols. Therefore, it was deemed important to find an accurate, convenient, and less expensive method for determination of the plasma homocysteine level and try to apply it into biomedical analytical laboratories to facilitate diagnosis and treatment.

    Objectives:

    1. The project has endeavored to determine relationship between the plasma homocysteine level and the incidence of the cardiovascular diseases and arteriosclerosis in Egyptians.
    2. The project aims to introduce the determination of plasma homocysteine level s a marker to predict the candidates for arteriosclerosis and cardiovascular disorders.
    3. This project will try to develop, a simple, sensitive and rapid analytical method for the determination of the plasma homocysteine to be used in the general medical screening protocols.
    4. To assess a therapeutic and prophylactic protocol to Egyptian candidate for arteriosclerosis.

  • دراسة لزيادة تصويب وتوزيع بعض الادويه المضادة للاورام والمضادة للميكروبات إلى المخ
    ميزانية المشروع 100000 جنيه
    تاريخ البدء 16/9/2000
    تاريخ الإنتهاء عامان
    الباحث الرئيسي الأستاذ الدكتور / محسن عبد الفتاح هداية
    الهدف من المشروع

    Morbidity caused by brain dysfunction affects a grate number of persons all-over the world . Although new neuropharmaceuticals have the potential for trading specific brain diseases, they may not distribute to the brain in sufficient quantities. In the 1990x, the Decade of the Brain, several trials had been made in the field of drug development and design. Unfortunately, many drugs developed from rational drug design have questionable effectiveness as neuropharmaceuticals due to the inability of these drugs to transport across the brain capillary wall, which makes up the blood bain barrier in-vivo. The importance of developing effective neuropharmaceuticals emphasizes the need to develop new approaches to enhance drug delivery to the brain.

    Targeted drug delivery to the brain has a great benefit in overcoming many problems encountered in the treatment of brain diseases. These problems are mainly the drug transport through blood brain barrier (BBB) and the use of high doses of conventional dosage forms to deliver effective amount of the drug to the brain. Consequently, the side effects and toxicity caused by high doses as well as distribution of the drug to other tissues and organs present a serious problem that is manifested clearly with antineoplastic and antimicrobial agents.

    There are many examples for clinical problems encountered with the treatment of brain diseases, which can be solved by targeted drug delivery to the brain. As am example, the role of chemothererapy for primary brain malignancies is uncertain, in part because of the difficulty in finding agents that can cross the blood brain barrier. The nitrosoureas such as carmustin and lomustine have been the drugs  most frequently used, because of their lipid solubility. However, despite the fact that these drugs can cross the blood brain barrier, they have very serious adverse effects like delayed and cumulative bone-marrow depression, pulmonary fibrosis, renal and hepatic damage, and optic neuritis. These side effects are mainly due to the high dose of drug and the non selective drug distribution. So, targeted drug delivery to the brain is expected to be the ideal solution for this problem . Another example is the use of antibiotics such as the third generation cephalosporins (e.g. cefotaxime and ceftazidime) with broad spectrum bactericidal activity in the treatment of brain abscesses. Very high doses are required to attain therapeutic concentrations in the cerebrospinal fluid with subsequent high incidences of side effects. So , targeted drug delivery to the sit of action, which minimizes the exposure of other tissues to the drug, may avoid adverse toxicity.

    Numerous techniques have been developed in the site specific delivery area. Drug delivery systems using colloidal particulate carriers such as liposome's, proliposomes, noisome and proniosomes have distinct advantages over conventional dosage forms. This is because particles can act a drug containing reservoirs and modification of the particle composition or surface can adjust the drug release rate  and/or the affinity for target site. Liposome's have attracted considerable interest because of their factorable characteristics as drug carriers., The biodistribution of liposome's in-vivo has been studied exhaustively in the last decade. Proliposomes were introduced in 1986 to overcome the probles of physical stability of liposome's  in aqueous suspension. A second alternative to overcome such problems is the formation of noisome. The noisome are liposome- like vesicles prepared from hydrated mixtures of cholesterol and non- ionic surfactant. Noisome can entrap solutes, are quite stable, and require no special conditions for production and storage.

    Objectives:
    This project is directed toward the delivery of selected antineoplastic and antimicrobial agents to the brain enhancement of their transport through the blood brain barrier. This means increasing the therapeutic effect, decreasing the incidence of side effects and reducing the dose and dosage regimen.

    HyperLink

      HyperLink




  •    
       البريد الإلكترونى
      
                     
    مقترح / شكوي


    كيفية اعداد صفحة على موقع researchgate
    كيفية إنشاء حساب على google scholar‎
    عرض كيفية تحديث بيانات عضو هيئة التدريس  
    للتسجيل ولتحميل برامج مايكروسوفت
    استبيان التصنيفات الدولية للجامعات 
    دورة تدريبية عن Scopus
    web counter عدد زوار الموقع جميع الحقوق محفوظة لمشروع البوابة الإلكترونية - جامعة طنطا